A carregar...
Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis
BACKGROUND: Immunoglobulin light-chain amyloidosis (AL amyloidosis) is a rare and often fatal disease for which there is currently no treatment approved by the US Food and Drug Administration or the European Medicines Agency. Treatment options, which are typically based on therapies for multiple mye...
Na minha lista:
| Publicado no: | Am Health Drug Benefits |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Engage Healthcare Communications, LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6306096/ https://ncbi.nlm.nih.gov/pubmed/30647830 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|